Biegel JA: Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus. 2006, 20 (1): E11
Article
PubMed
Google Scholar
Biegel JA, Kalpana G, Knudsen ES, Packer RJ, Roberts CW, Thiele CJ, Weissman B, Smith M: The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 2002, 62 (1): 323-328.
CAS
PubMed
Google Scholar
Packer RJ, Biegel JA, Blaney S, Finlay J, Geyer JR, Heideman R, Hilden J, Janss AJ, Kun L, Vezina G: Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002, 24 (5): 337-342. 10.1097/00043426-200206000-00004.
Article
PubMed
Google Scholar
Strother D: Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther. 2005, 5 (5): 907-915. 10.1586/14737140.5.5.907.
Article
PubMed
Google Scholar
Reddy AT: Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol. 2005, 75 (3): 309-313. 10.1007/s11060-005-6762-8.
Article
CAS
PubMed
Google Scholar
Yamamoto M, Suzuki N, Hatakeyama N, Mizue N, Hori T, Kuroiwa Y, Hareyama M, Oda T, Kudoh T, Nui A: Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report. J Pediatr Hematol Oncol. 2006, 28 (5): 286-289. 10.1097/01.mph.0000212901.84146.5a.
Article
PubMed
Google Scholar
Alarcon-Vargas D, Zhang Z, Agarwal B, Challagulla K, Mani S, Kalpana GV: Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene. 2006, 25 (5): 722-734. 10.1038/sj.onc.1209112.
Article
CAS
PubMed
Google Scholar
Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV: Genetic ablation of CyclinD1 abrogates rhabdoid tumours arising due to Ini1 loss. Proc Natl Acad Sci USA. 2005,
Google Scholar
Dipietrantonio A, Hsieh TC, Wu JM: Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun. 1996, 224 (3): 837-842. 10.1006/bbrc.1996.1109.
Article
CAS
PubMed
Google Scholar
Formelli F, Camerini T, Cavadini E, Appierto V, Villani MG, Costa A, De Palo G, Di Mauro MG, Veronesi U: Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemiol Biomarkers Prev. 2003, 12 (1): 34-41.
CAS
PubMed
Google Scholar
Hail N, Kim HJ, Lotan R: Mechanisms of fenretinide-induced apoptosis. Apoptosis. 2006, 11 (10): 1677-1694. 10.1007/s10495-006-9289-3.
Article
CAS
PubMed
Google Scholar
Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z: N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res. 2003, 27 (3): 259-266. 10.1016/S0145-2126(02)00162-5.
Article
CAS
PubMed
Google Scholar
Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F: The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res. 2009, 15 (4): 1199-1209. 10.1158/1078-0432.CCR-08-2477.
Article
CAS
PubMed
Google Scholar
Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res. 2003, 9 (6): 2032-2039.
CAS
PubMed
Google Scholar
Fontana JA, Rishi AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia. 2002, 16 (4): 463-472. 10.1038/sj.leu.2402414.
Article
CAS
PubMed
Google Scholar
Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A: Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. 2006, 13 (1): 51-68. 10.1677/erc.1.00938.
Article
CAS
PubMed
Google Scholar
Lovat PE, Corazzari M, Di Sano F, Piacentini M, Redfern CP: The role of gangliosides in fenretinide-induced apoptosis of neuroblastoma. Cancer Lett. 2005, 228 (1-2): 105-110. 10.1016/j.canlet.2005.01.044.
Article
CAS
PubMed
Google Scholar
Lovat PE, Corazzari M, Goranov B, Piacentini M, Redfern CP: Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Ann N Y Acad Sci. 2004, 1028: 81-89. 10.1196/annals.1322.009.
Article
CAS
PubMed
Google Scholar
Reynolds CP: Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant. 2004, 8 (Suppl 5): 56-66.
Article
PubMed
Google Scholar
Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ: Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003, 197 (1-2): 185-192. 10.1016/S0304-3835(03)00108-3.
Article
CAS
PubMed
Google Scholar
DiPietrantonio AM, Hsieh TC, Olson SC, Wu JM: Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer. 1998, 78 (1): 53-61. 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6.
Article
CAS
PubMed
Google Scholar
Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ: Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol. 2000, 35 (6): 597-602. 10.1002/1096-911X(20001201)35:6<597::AID-MPO23>3.0.CO;2-B.
Article
CAS
PubMed
Google Scholar
Pirkmaier A, Yuen K, Hendley J, O'Connell MJ, Germain D: Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide. Clin Cancer Res. 2003, 9: 1877-1884.
CAS
PubMed
Google Scholar
Abou-Issa H, Curley RW, Alshafie GA, Weiss KL, Clagett-Dame M, Chapman JS, Mershon SM: Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis. Anticancer Res. 2001, 21 (6A): 3839-3844.
CAS
PubMed
Google Scholar
Winum JY, Leydet A, Seman M, Montero JL: Synthesis and biological activity of glycosyl conjugates of N-(4-hydroxyphenyl)retinamide. Farmaco. 2001, 56 (4): 319-324. 10.1016/S0014-827X(01)01074-6.
Article
CAS
PubMed
Google Scholar
Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, Clagett-Dame M, Curley RW, Formelli F: 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res. 2006, 66 (6): 3238-3247. 10.1158/0008-5472.CAN-05-3362.
Article
CAS
PubMed
Google Scholar
Das BC, Smith ME, Kalpana GV: Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors. Bioorg Med Chem Lett. 2008, 18 (14): 4177-4180. 10.1016/j.bmcl.2008.05.097.
Article
CAS
PubMed
Google Scholar
Das BC, Smith ME, Kalpana GV: Design and synthesis of 4-HPR derivatives for rhabdoid tumors. Bioorg Med Chem Lett. 2008, 18 (13): 3805-3808. 10.1016/j.bmcl.2008.05.021.
Article
CAS
PubMed
Google Scholar
Gentilucci L, Tolomelli A, Squassabia F: Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem. 2006, 13 (20): 2449-2466. 10.2174/092986706777935041.
Article
CAS
PubMed
Google Scholar
Siddikuzzaman Guruvayoorappan C, Berlin Grace VM: All Trans Retinoic Acid and Cancer. Immunopharmacol Immunotoxicol. 2010
Google Scholar
Hoffman E, Mielicki WP: [All-trans retinoic acid (ATRA) in prevention and cancer therapy]. Postepy Hig Med Dosw (Online). 2010, 64: 284-290.
Google Scholar
Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV: Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci USA. 2005, 102 (34): 12129-12134. 10.1073/pnas.0505300102.
Article
PubMed Central
CAS
PubMed
Google Scholar
Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB: Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res. 2004, 10 (7): 2570-2577. 10.1158/1078-0432.CCR-03-0271.
Article
CAS
PubMed
Google Scholar
Rehman F, Shanmugasundaram P, Schrey MP: Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Br J Cancer. 2004, 91 (10): 1821-1828. 10.1038/sj.bjc.6602212.
Article
PubMed Central
CAS
PubMed
Google Scholar
Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM: N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis. 2005, 26 (5): 1000-1007.
Article
CAS
PubMed
Google Scholar
Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP: Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res. 1999, 5 (8): 2230-2235.
PubMed Central
CAS
PubMed
Google Scholar
Tiwari M, Kumar A, Sinha RA, Shrivastava A, Balapure AK, Sharma R, Bajpai VK, Mitra K, Babu S, Godbole MM: Mechanism of 4-HPR-induced apoptosis in glioma cells: evidences suggesting role of mitochondrial-mediated pathway and endoplasmic reticulum stress. Carcinogenesis. 2006, 27 (10): 2047-2058. 10.1093/carcin/bgl051.
Article
CAS
PubMed
Google Scholar
Das A, Banik NL, Ray SK: N-(4-Hydroxyphenyl) retinamide induced both differentiation and apoptosis in human glioblastoma T98G and U87MG cells. Brain Res. 2008, 1227: 207-215.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bonanni B, Lazzeroni M, Veronesi U: Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther. 2007, 7 (4): 423-432. 10.1586/14737140.7.4.423.
Article
CAS
PubMed
Google Scholar
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999, 91 (21): 1847-1856. 10.1093/jnci/91.21.1847.
Article
CAS
PubMed
Google Scholar
Cavalla P, Dutto A, Piva R, Richiardi P, Grosso R, Schiffer D: Cyclin D1 expression in gliomas. Acta Neuropathol. 1998, 95 (2): 131-135. 10.1007/s004010050776.
Article
CAS
PubMed
Google Scholar
Sutherland RL, Musgrove EA: Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004, 9 (1): 95-104.
Article
PubMed
Google Scholar
Simoni D, Invidiata FP, Rondanin R, Grimaudo S, Cannizzo G, Barbusca E, Porretto F, D'Alessandro N, Tolomeo M: Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid. J Med Chem. 1999, 42 (24): 4961-4969. 10.1021/jm991059n.
Article
CAS
PubMed
Google Scholar
Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998, 394 (6689): 203-206. 10.1038/28212.
Article
CAS
PubMed
Google Scholar
Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV: Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol. 2002, 22 (16): 5975-5988. 10.1128/MCB.22.16.5975-5988.2002.
Article
PubMed Central
CAS
PubMed
Google Scholar